{
    "nctId": "NCT00546156",
    "briefTitle": "Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer",
    "officialTitle": "A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 104,
    "primaryOutcomeMeasure": "Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Documented primary invasive breast cancer by histologic assessment\n* Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis\n* Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol\n* 18 year of age or older\n* Performance status of 0 or 1 by ECOG criteria\n* Use of an effective means of contraception in subjects of childbearing potential\n* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy.\n* Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment\n* Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer\n* No other malignancy that requires on-going treatment\n* Normal organ function as outlined in the protocol\n\nExclusion Criteria:\n\n* Prior cytotoxic chemotherapy or radiation for the current breast cancer\n* Patients with inflammatory breast cancer\n* HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH\n* Known metastatic (Stage IV) disease\n* Other investigational agents within 4 weeks prior to the start of study treatment\n* Life expectancy of less than 6 months\n* Peripheral neuropathy greater than or equal to grade 2\n* Inadequately controlled hypertension\n* Any prior history of hypertensive crisis or hypertensive encephalopathy\n* NYHA grade II or greater congestive heart failure\n* History of prior myocardial infarction\n* History of unstable angina within 12 months prior to study enrollment\n* Any history of stroke or transient ischemic attack at any time\n* Known CNS disease\n* Significant vascular disease\n* Symptomatic peripheral vascular disease\n* Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study.\n* Known HIV positive\n* Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue\n* Pregnant of lactating\n* Known hypersensitivity to any component of bevacizumab",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}